

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 January 2006 (05.01.2006)

PCT

(10) International Publication Number
WO 2006/000420 A1(51) International Patent Classification⁷: **C07D 239/48**,
409/12, 401/12, 405/12, 403/12, A61K 31/505, 31/506,
C07D 251/48, A61P 35/00(21) International Application Number:
PCT/EP2005/006815

(22) International Filing Date: 23 June 2005 (23.06.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/582,425 24 June 2004 (24.06.2004) US
0512324.5 16 June 2005 (16.06.2005) GB(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).(71) Applicant (for all designated States except US): **IRMLLC** [US/—]; 'Hurst Holme', 12 Trott Road, Hamilton, HM 11 (BM).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DING, Qiang** [CN/US]; 11686 Carmel Creek Road #204, San Diego, CA 92130 (US). **GRAY, Nathanael, Schiander** [US/US]; 5652 Lamas Street, San Diego, CA 92122 (US). **LI, Bing** [CN/US]; 9675 Genesee Avenue, Apt. I-1, San Diego, CA 92121 (US). **LIU, Yi** [CN/US]; 4255 Corte de Sausalito, San Diego, CA 92130 (US). **SIM, Taebo** [KR/US]; 12664 Torrey Bluff Drive, Apt. No. 212, San Diego, CA 92130 (US). **UNO, Tetsuo** [JP/US]; 4495 Shorepointe Way, San Diego, CA 92130 (US). **ZHANG, Guobao** [CN/US]; 8730 Costa Verde Blvd. #2237, San Diego, CA 92122 (US). **PISSOT SOLDERMANN, Carole** [FR/FR]; 2, rue des Maraichers, F-68128 Rosenau (FR). **BREITENSTEIN, Werner** [CH/CH]; St. Galler-Ring 179, CH-4054Basel (CH). **BOLD, Guido** [CH/CH]; Bleumatthöhe 16, CH-5073 Gipf-Oberfrick (CH). **CARAVATTI, Giorgio** [CH/CH]; Fuchshagweg 28, CH-4103 Bottmingen (CH). **FURET, Pascal** [FR/FR]; 24, rue du Riegelsbourg, F-68800 Thann (FR). **GUAGNANO, Vito** [IT/CH]; Thannerstrasse 66, CH-4054 Basel (CH). **LANG, Marc** [FR/FR]; 24, rue de Valdoie, F-68200 Mulhouse (FR). **MANLEY, Paul, W.** [GB/CH]; Bruggweg 12, CH-4144 Arlesheim (CH). **SCHOEPFER, Joseph** [CH/CH]; Steingrubenweg 112, CH-4125 Riehen (CH). **SPANKA, Carsten** [DE/DE]; Bergfriedweg 1e, 79541 Lörrach (DE).(74) Agent: **ROTH, Peter, R.**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

(57) Abstract: The invention relates to compounds of formula (I) wherein the substituents X¹, R¹, R², R³ and R⁴ have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.